Thirty-day mortality rates after immunotherapy initiation
The aim of this study was to determine the cause of death in patients who died within 30 days after the first dose of immunotherapy. The data of 1432 patients treated with immunotherapy in six tertiary referral hospitals were retrospectively analyzed. It was determined that 34 (2%) of the patients d...
Gespeichert in:
| Veröffentlicht in: | Immunotherapy 2021-12, Vol.13 (17), p.1419-1426 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1426 |
|---|---|
| container_issue | 17 |
| container_start_page | 1419 |
| container_title | Immunotherapy |
| container_volume | 13 |
| creator | Sütcüoğlu, Osman İlhan, Ayşegül Tacar, Seher Yıldız Güven, Deniz Can Uçar, Gökhan Karadurmuş, Nuri Yıldız, Fatih Eraslan, Emrah Uncu, Doğan Tural, Deniz Üner, Aytuğ Günel, Nazan Özdemir, Nuriye Kılıçkap, Saadettin Öksüzoğlu, Ömür Berna Özet, Ahmet Yazıcı, Ozan |
| description | The aim of this study was to determine the cause of death in patients who died within 30 days after the first dose of immunotherapy.
The data of 1432 patients treated with immunotherapy in six tertiary referral hospitals were retrospectively analyzed.
It was determined that 34 (2%) of the patients died within 30 days after the first dose of immunotherapy. Death occurred in all patients who received palliative therapy, and most patients (88%) received immunotherapy as second- or subsequent-line of therapy. The most common cause of death was disease progression and thromboembolic events.
Preliminary results of the current study might give some clues to define the patient population in whom the fatal side effects of immunotherapy might be encountered. |
| doi_str_mv | 10.2217/imt-2021-0082 |
| format | Article |
| fullrecord | <record><control><sourceid>futurescience_cross</sourceid><recordid>TN_cdi_crossref_primary_10_2217_imt_2021_0082</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>10_2217_imt_2021_0082</sourcerecordid><originalsourceid>FETCH-LOGICAL-c320t-3076f34fec89149aae4dc0e0923b9c5492b0c329b5b43c9031e02e3c2e8f93183</originalsourceid><addsrcrecordid>eNp1j0tLxDAUhYMoOI4u3fcPRG8efWQpgy8YcDOCu5CmN0xk0g5Juui_t6XiztU9F75z4CPknsED56x-9CFTDpxRgIZfkA2rS6C1lM3lXxZf1-QmpW-AStaV3BB1OPqYJ9qZqQhDzObk81REkzEVxmWMhQ9h7Id8xGjOU-F7n73JfuhvyZUzp4R3v3dLPl-eD7s3uv94fd897akVHDIVUFdOSIe2UUwqY1B2FhAUF62ypVS8hZlUbdlKYRUIhsBRWI6NU4I1YkvoumvjkFJEp8_RBxMnzUAv3nr21ou3XrxnXq28G_MYMVmPvUW9fgE7b32P_3R_ADs_X7c</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Thirty-day mortality rates after immunotherapy initiation</title><source>PubMed Central</source><creator>Sütcüoğlu, Osman ; İlhan, Ayşegül ; Tacar, Seher Yıldız ; Güven, Deniz Can ; Uçar, Gökhan ; Karadurmuş, Nuri ; Yıldız, Fatih ; Eraslan, Emrah ; Uncu, Doğan ; Tural, Deniz ; Üner, Aytuğ ; Günel, Nazan ; Özdemir, Nuriye ; Kılıçkap, Saadettin ; Öksüzoğlu, Ömür Berna ; Özet, Ahmet ; Yazıcı, Ozan</creator><creatorcontrib>Sütcüoğlu, Osman ; İlhan, Ayşegül ; Tacar, Seher Yıldız ; Güven, Deniz Can ; Uçar, Gökhan ; Karadurmuş, Nuri ; Yıldız, Fatih ; Eraslan, Emrah ; Uncu, Doğan ; Tural, Deniz ; Üner, Aytuğ ; Günel, Nazan ; Özdemir, Nuriye ; Kılıçkap, Saadettin ; Öksüzoğlu, Ömür Berna ; Özet, Ahmet ; Yazıcı, Ozan</creatorcontrib><description>The aim of this study was to determine the cause of death in patients who died within 30 days after the first dose of immunotherapy.
The data of 1432 patients treated with immunotherapy in six tertiary referral hospitals were retrospectively analyzed.
It was determined that 34 (2%) of the patients died within 30 days after the first dose of immunotherapy. Death occurred in all patients who received palliative therapy, and most patients (88%) received immunotherapy as second- or subsequent-line of therapy. The most common cause of death was disease progression and thromboembolic events.
Preliminary results of the current study might give some clues to define the patient population in whom the fatal side effects of immunotherapy might be encountered.</description><identifier>ISSN: 1750-743X</identifier><identifier>EISSN: 1750-7448</identifier><identifier>DOI: 10.2217/imt-2021-0082</identifier><language>eng</language><publisher>Future Medicine Ltd</publisher><subject>antiaggregant drugs ; atezolizumab ; cancer ; fatal side effects ; hyperprogression ; immune side effect ; immunotherapy ; nivolumab ; palliative oncology ; thromboembolism</subject><ispartof>Immunotherapy, 2021-12, Vol.13 (17), p.1419-1426</ispartof><rights>2021 Future Medicine Ltd</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c320t-3076f34fec89149aae4dc0e0923b9c5492b0c329b5b43c9031e02e3c2e8f93183</citedby><cites>FETCH-LOGICAL-c320t-3076f34fec89149aae4dc0e0923b9c5492b0c329b5b43c9031e02e3c2e8f93183</cites><orcidid>0000-0001-8731-9636 ; 0000-0003-3152-6008 ; 0000-0003-2497-5913 ; 0000-0003-1637-7390 ; 0000-0002-0929-3271 ; 0000-0003-0038-3569 ; 0000-0002-2756-8646 ; 0000-0001-7581-0962 ; 0000-0003-2144-6469 ; 0000-0003-3836-3854 ; 0000-0003-3835-2741 ; 0000-0003-3291-8062 ; 0000-0002-9235-9592 ; 0000-0003-2295-7332 ; 0000-0002-6924-9467 ; 0000-0002-0333-1388 ; 0000-0002-7649-1075</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids></links><search><creatorcontrib>Sütcüoğlu, Osman</creatorcontrib><creatorcontrib>İlhan, Ayşegül</creatorcontrib><creatorcontrib>Tacar, Seher Yıldız</creatorcontrib><creatorcontrib>Güven, Deniz Can</creatorcontrib><creatorcontrib>Uçar, Gökhan</creatorcontrib><creatorcontrib>Karadurmuş, Nuri</creatorcontrib><creatorcontrib>Yıldız, Fatih</creatorcontrib><creatorcontrib>Eraslan, Emrah</creatorcontrib><creatorcontrib>Uncu, Doğan</creatorcontrib><creatorcontrib>Tural, Deniz</creatorcontrib><creatorcontrib>Üner, Aytuğ</creatorcontrib><creatorcontrib>Günel, Nazan</creatorcontrib><creatorcontrib>Özdemir, Nuriye</creatorcontrib><creatorcontrib>Kılıçkap, Saadettin</creatorcontrib><creatorcontrib>Öksüzoğlu, Ömür Berna</creatorcontrib><creatorcontrib>Özet, Ahmet</creatorcontrib><creatorcontrib>Yazıcı, Ozan</creatorcontrib><title>Thirty-day mortality rates after immunotherapy initiation</title><title>Immunotherapy</title><description>The aim of this study was to determine the cause of death in patients who died within 30 days after the first dose of immunotherapy.
The data of 1432 patients treated with immunotherapy in six tertiary referral hospitals were retrospectively analyzed.
It was determined that 34 (2%) of the patients died within 30 days after the first dose of immunotherapy. Death occurred in all patients who received palliative therapy, and most patients (88%) received immunotherapy as second- or subsequent-line of therapy. The most common cause of death was disease progression and thromboembolic events.
Preliminary results of the current study might give some clues to define the patient population in whom the fatal side effects of immunotherapy might be encountered.</description><subject>antiaggregant drugs</subject><subject>atezolizumab</subject><subject>cancer</subject><subject>fatal side effects</subject><subject>hyperprogression</subject><subject>immune side effect</subject><subject>immunotherapy</subject><subject>nivolumab</subject><subject>palliative oncology</subject><subject>thromboembolism</subject><issn>1750-743X</issn><issn>1750-7448</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNp1j0tLxDAUhYMoOI4u3fcPRG8efWQpgy8YcDOCu5CmN0xk0g5Juui_t6XiztU9F75z4CPknsED56x-9CFTDpxRgIZfkA2rS6C1lM3lXxZf1-QmpW-AStaV3BB1OPqYJ9qZqQhDzObk81REkzEVxmWMhQ9h7Id8xGjOU-F7n73JfuhvyZUzp4R3v3dLPl-eD7s3uv94fd897akVHDIVUFdOSIe2UUwqY1B2FhAUF62ypVS8hZlUbdlKYRUIhsBRWI6NU4I1YkvoumvjkFJEp8_RBxMnzUAv3nr21ou3XrxnXq28G_MYMVmPvUW9fgE7b32P_3R_ADs_X7c</recordid><startdate>20211201</startdate><enddate>20211201</enddate><creator>Sütcüoğlu, Osman</creator><creator>İlhan, Ayşegül</creator><creator>Tacar, Seher Yıldız</creator><creator>Güven, Deniz Can</creator><creator>Uçar, Gökhan</creator><creator>Karadurmuş, Nuri</creator><creator>Yıldız, Fatih</creator><creator>Eraslan, Emrah</creator><creator>Uncu, Doğan</creator><creator>Tural, Deniz</creator><creator>Üner, Aytuğ</creator><creator>Günel, Nazan</creator><creator>Özdemir, Nuriye</creator><creator>Kılıçkap, Saadettin</creator><creator>Öksüzoğlu, Ömür Berna</creator><creator>Özet, Ahmet</creator><creator>Yazıcı, Ozan</creator><general>Future Medicine Ltd</general><scope>AAYXX</scope><scope>CITATION</scope><orcidid>https://orcid.org/0000-0001-8731-9636</orcidid><orcidid>https://orcid.org/0000-0003-3152-6008</orcidid><orcidid>https://orcid.org/0000-0003-2497-5913</orcidid><orcidid>https://orcid.org/0000-0003-1637-7390</orcidid><orcidid>https://orcid.org/0000-0002-0929-3271</orcidid><orcidid>https://orcid.org/0000-0003-0038-3569</orcidid><orcidid>https://orcid.org/0000-0002-2756-8646</orcidid><orcidid>https://orcid.org/0000-0001-7581-0962</orcidid><orcidid>https://orcid.org/0000-0003-2144-6469</orcidid><orcidid>https://orcid.org/0000-0003-3836-3854</orcidid><orcidid>https://orcid.org/0000-0003-3835-2741</orcidid><orcidid>https://orcid.org/0000-0003-3291-8062</orcidid><orcidid>https://orcid.org/0000-0002-9235-9592</orcidid><orcidid>https://orcid.org/0000-0003-2295-7332</orcidid><orcidid>https://orcid.org/0000-0002-6924-9467</orcidid><orcidid>https://orcid.org/0000-0002-0333-1388</orcidid><orcidid>https://orcid.org/0000-0002-7649-1075</orcidid></search><sort><creationdate>20211201</creationdate><title>Thirty-day mortality rates after immunotherapy initiation</title><author>Sütcüoğlu, Osman ; İlhan, Ayşegül ; Tacar, Seher Yıldız ; Güven, Deniz Can ; Uçar, Gökhan ; Karadurmuş, Nuri ; Yıldız, Fatih ; Eraslan, Emrah ; Uncu, Doğan ; Tural, Deniz ; Üner, Aytuğ ; Günel, Nazan ; Özdemir, Nuriye ; Kılıçkap, Saadettin ; Öksüzoğlu, Ömür Berna ; Özet, Ahmet ; Yazıcı, Ozan</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c320t-3076f34fec89149aae4dc0e0923b9c5492b0c329b5b43c9031e02e3c2e8f93183</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>antiaggregant drugs</topic><topic>atezolizumab</topic><topic>cancer</topic><topic>fatal side effects</topic><topic>hyperprogression</topic><topic>immune side effect</topic><topic>immunotherapy</topic><topic>nivolumab</topic><topic>palliative oncology</topic><topic>thromboembolism</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sütcüoğlu, Osman</creatorcontrib><creatorcontrib>İlhan, Ayşegül</creatorcontrib><creatorcontrib>Tacar, Seher Yıldız</creatorcontrib><creatorcontrib>Güven, Deniz Can</creatorcontrib><creatorcontrib>Uçar, Gökhan</creatorcontrib><creatorcontrib>Karadurmuş, Nuri</creatorcontrib><creatorcontrib>Yıldız, Fatih</creatorcontrib><creatorcontrib>Eraslan, Emrah</creatorcontrib><creatorcontrib>Uncu, Doğan</creatorcontrib><creatorcontrib>Tural, Deniz</creatorcontrib><creatorcontrib>Üner, Aytuğ</creatorcontrib><creatorcontrib>Günel, Nazan</creatorcontrib><creatorcontrib>Özdemir, Nuriye</creatorcontrib><creatorcontrib>Kılıçkap, Saadettin</creatorcontrib><creatorcontrib>Öksüzoğlu, Ömür Berna</creatorcontrib><creatorcontrib>Özet, Ahmet</creatorcontrib><creatorcontrib>Yazıcı, Ozan</creatorcontrib><collection>CrossRef</collection><jtitle>Immunotherapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sütcüoğlu, Osman</au><au>İlhan, Ayşegül</au><au>Tacar, Seher Yıldız</au><au>Güven, Deniz Can</au><au>Uçar, Gökhan</au><au>Karadurmuş, Nuri</au><au>Yıldız, Fatih</au><au>Eraslan, Emrah</au><au>Uncu, Doğan</au><au>Tural, Deniz</au><au>Üner, Aytuğ</au><au>Günel, Nazan</au><au>Özdemir, Nuriye</au><au>Kılıçkap, Saadettin</au><au>Öksüzoğlu, Ömür Berna</au><au>Özet, Ahmet</au><au>Yazıcı, Ozan</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Thirty-day mortality rates after immunotherapy initiation</atitle><jtitle>Immunotherapy</jtitle><date>2021-12-01</date><risdate>2021</risdate><volume>13</volume><issue>17</issue><spage>1419</spage><epage>1426</epage><pages>1419-1426</pages><issn>1750-743X</issn><eissn>1750-7448</eissn><abstract>The aim of this study was to determine the cause of death in patients who died within 30 days after the first dose of immunotherapy.
The data of 1432 patients treated with immunotherapy in six tertiary referral hospitals were retrospectively analyzed.
It was determined that 34 (2%) of the patients died within 30 days after the first dose of immunotherapy. Death occurred in all patients who received palliative therapy, and most patients (88%) received immunotherapy as second- or subsequent-line of therapy. The most common cause of death was disease progression and thromboembolic events.
Preliminary results of the current study might give some clues to define the patient population in whom the fatal side effects of immunotherapy might be encountered.</abstract><pub>Future Medicine Ltd</pub><doi>10.2217/imt-2021-0082</doi><tpages>8</tpages><orcidid>https://orcid.org/0000-0001-8731-9636</orcidid><orcidid>https://orcid.org/0000-0003-3152-6008</orcidid><orcidid>https://orcid.org/0000-0003-2497-5913</orcidid><orcidid>https://orcid.org/0000-0003-1637-7390</orcidid><orcidid>https://orcid.org/0000-0002-0929-3271</orcidid><orcidid>https://orcid.org/0000-0003-0038-3569</orcidid><orcidid>https://orcid.org/0000-0002-2756-8646</orcidid><orcidid>https://orcid.org/0000-0001-7581-0962</orcidid><orcidid>https://orcid.org/0000-0003-2144-6469</orcidid><orcidid>https://orcid.org/0000-0003-3836-3854</orcidid><orcidid>https://orcid.org/0000-0003-3835-2741</orcidid><orcidid>https://orcid.org/0000-0003-3291-8062</orcidid><orcidid>https://orcid.org/0000-0002-9235-9592</orcidid><orcidid>https://orcid.org/0000-0003-2295-7332</orcidid><orcidid>https://orcid.org/0000-0002-6924-9467</orcidid><orcidid>https://orcid.org/0000-0002-0333-1388</orcidid><orcidid>https://orcid.org/0000-0002-7649-1075</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1750-743X |
| ispartof | Immunotherapy, 2021-12, Vol.13 (17), p.1419-1426 |
| issn | 1750-743X 1750-7448 |
| language | eng |
| recordid | cdi_crossref_primary_10_2217_imt_2021_0082 |
| source | PubMed Central |
| subjects | antiaggregant drugs atezolizumab cancer fatal side effects hyperprogression immune side effect immunotherapy nivolumab palliative oncology thromboembolism |
| title | Thirty-day mortality rates after immunotherapy initiation |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T18%3A33%3A38IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-futurescience_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Thirty-day%20mortality%20rates%20after%20immunotherapy%20initiation&rft.jtitle=Immunotherapy&rft.au=S%C3%BCtc%C3%BCo%C4%9Flu,%20Osman&rft.date=2021-12-01&rft.volume=13&rft.issue=17&rft.spage=1419&rft.epage=1426&rft.pages=1419-1426&rft.issn=1750-743X&rft.eissn=1750-7448&rft_id=info:doi/10.2217/imt-2021-0082&rft_dat=%3Cfuturescience_cross%3E10_2217_imt_2021_0082%3C/futurescience_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |